FY16 Q4 Quarterly Activity Report + Appendix 4C
October 28, 2016. Melbourne, Australia.
Respiratory technology company Rhinomed Limited (ASX: RNO) is pleased to report continued good quarter on quarter growth in operational revenue during Q1, FY17.
Sales Momentum continues
Receipts from Customers increased to $539k (up 59% from $340k) in parallel as receipts from both direct to consumer and sales through major retailers were received. Cash burn for the quarter dropped 48%. The change is reflective of both an increase in store numbers and also the early impact of promotional activities.
Pleasingly, Revenue from the sale of its Mute and Turbine products experienced a continued solid increase growing from $298k to $533k, up 79% from the previous quarter. Following on a full financial FY16 revenues of $1.01M, this FY17 Q1 result reflects the strong sales momentum now underway.